Proactive Investors
25 Aug 2026, 06:31 UTC · 1h ago
Solvonis raises £1.3m to fund three clinical programmes
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
25 Aug 2026, 06:31 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Solvonis Therapeutics raised £1.3 million through a share placing of 1.08 billion new shares at 0.12p each. — While providing necessary liquidity, a large share placing typically causes immediate dilution for existing shareholders.
-0.40The National Institute on Drug Abuse selected SVN-015 for further evaluation under its Addiction Treatment Discovery Program. — Third-party validation from a major health institute reduces perceived technical risk for the discovery-stage compound.
+0.30Solvonis is seeking to add European Union trial sites to its Phase 3 trial for SVN-001 to strengthen future regulatory submissions in European markets. — Expanding the dataset to include international patients increases the potential addressable market and regulatory success probability.
+0.20Continue reading
6 related stories
Search tags
The company is using the FDA's 505(b)(2) pathway for its SVN-002 program to leverage existing data from an approved reference product. — This regulatory pathway typically allows for a faster and less expensive route to market than standard new drug applications.
+0.20Turner Pope Investments has replaced Singer Capital Markets as the company's corporate broker. — Brokerage changes are common administrative shifts and usually have neutral immediate price impact.
+0.00Which stocks this story touches
The company successfully raised £1.3 million, attracted a new institutional investor, and reported positive preclinical data and program selection by the NIDA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
16h ago
